Enanta Pharmaceuticals Inc. (ENTA) Income Statement Analysis - Revenue, Earnings & Profitability Metrics - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Enanta Pharmaceuticals In...

    NASDAQ: ENTA · Real-Time Price · USD
    8.85
    -0.04 (-0.45%)
    At close: Sep 05, 2025, 3:59 PM
    8.99
    1.58%
    After-hours: Sep 05, 2025, 06:35 PM EDT

    Enanta Pharmaceuticals Income Statement

    Financials in USD. Fiscal year is October - September.

    undefined peaked at n/a in undefined and hit its lowest at n/a in undefined. Over the past five years, it has declined by undefined%.

    Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
    Period Ending Sep 30, 2024 Sep 30, 2023 Sep 30, 2022 Sep 30, 2021
    Revenue
    		 67.64M 79.2M 86.16M 97.07M
    Cost of Revenue
    		 n/a 2.37M 2.97M n/a
    Gross Profit
    		 67.64M 79.2M 86.16M 97.07M
    Operating Income
    		 -121.69M -137.21M -123.84M -109.57M
    Interest Income
    		 14.77M 11.36M 1.57M 2.02M
    Pretax Income
    		 -117.79M -131M -122.19M -107.58M
    Net Income
    		 -116.05M -133.82M -121.75M -79M
    Selling & General & Admin
    		 57.85M 52.89M 45.48M 32.54M
    Research & Development
    		 131.48M 163.52M 164.52M 174.11M
    Other Expenses
    		 n/a n/a n/a n/a
    Operating Expenses
    		 189.33M 216.41M 210M 206.65M
    Interest Expense
    		 10.94M 5.15M n/a n/a
    Selling & Marketing Expenses
    		 n/a n/a n/a n/a
    Cost & Expenses
    		 189.33M 216.41M 210M 206.65M
    Income Tax Expense
    		 -1.74M 2.82M -433K -28.58M
    Shares Outstanding (Basic)
    		 21.16M 20.97M 20.6M 20.17M
    Shares Outstanding (Diluted)
    		 21.16M 20.97M 20.6M 20.17M
    EPS (Basic)
    		 -5.48 -6.38 -5.91 -3.92
    EPS (Diluted)
    		 -5.48 -6.38 -5.91 -3.92
    EBITDA
    		 -104.51M -123.48M -119.22M -104.25M
    EBIT
    		 -106.85M -125.85M -122.19M -107.58M
    Depreciation & Amortization
    		 2.34M 2.37M 2.97M 3.33M

    Add to Watchlist